secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001104659-23-072304
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma shareholders approve equity plan amendment increasing shares by 1M
--------------------------------------------------------------------------------

- Stockholders approved amendment to Global Equity Incentive Plan (2021) adding 1,000,000 shares and annual evergreen from 2024-2033.
- Ron Bentsur re-elected as Class I director with 9,035,321 votes for, 149,868 withheld, and 3,284,985 broker non-votes.
- Ratification of Kesselman & Kesselman as independent auditor for FY 2023 approved with 12,468,118 for, 616 against, 1 abstention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/0001104659-23-072304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465923072304/tm2318992d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-072304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer